The abstract is read at the publisher; the summary is JClub's.
αTIGIT-guided tandem IL-15Rβγ bispecifics (αTIGIT-αIL-15Rβγ) restore tumor-infiltrating T cell activity and show potent antitumor effects in vivo without detectable systemic toxicity even at high doses.
- Why it matters: Native cytokines are constrained by instability, short half-life, poor drug-like properties, and severe systemic toxicity, leaving uncertainty about whether antibody cytokine mimetics can work therapeutically in vivo.
- What they did: The team engineered tandem IL-15 mimetics using Alpaca-derived phage display with AlphaFold3-assisted structural screening and format comparisons, then built a tri-antibody αTIGIT-αIL-15Rβγ to target TILs.
- The result: In vivo, αTIGIT-αIL-15Rβγ enhanced CD8+ T effector function and expanded intratumoral stem-like T cells, supporting TIL-targeted cytokine mimetics as safer partners for immune checkpoint blockade.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.